Canagliflozin Hemihydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Canagliflozin Hemihydrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
240
Registered trials
175
Result records
6
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Canagliflozin Hemihydrate can convert its Small molecule drug profile and SGLT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Canagliflozin Hemihydrate (query alias: canagliflozin) |
|---|---|
| Modality / target | Small molecule drug; SGLT2; SGLT2 inhibitors |
| Highest global status | Approved |
| Originator | Tanabe Pharma Corp. |
| Active developers | Tanabe Pharma Corp., Johnson & Johnson, Janssen-Cilag International NV |
The MCP disease footprint includes Type 2 diabetes mellitus with established diabetic nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07547878 | Phase 4 | Not yet recruiting | 64 | On-study retention rate at 6 months |
| NCT07527390 | Phase 4 | Not yet recruiting | 10 | Overall drug tissue disposition of SGLT2 in patients on dialysis. |
| NCT07703163 | Phase 1 | Not yet recruiting | 15 | Number of Participants With Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
1846-P: Effects of Intensification of Canagliflozin from 100 mg to 300 mg Daily on Insulin Initiation in the INTENSIFY Study
Not Applicable; n=95; evaluation: Positive. Reported fields: A1c <7% = 49.4 %
Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial
Phase 2; n=45; evaluation: Positive. Reported fields: ECV: Difference (%) = -3.67(95.0% CI, -5.33 to -2.01), P-Value = <0.001; ECV = -3.67 %
Impact of Canagliflozin on Heart Stress and Outcomes: Pooled Insights from CREDENCE and CANVAS
Phase 3; n=5281; evaluation: Positive. Reported fields: Composite endpoint(kidney composite): HR = 0.65(95.0% CI, 0.53 - 0.79); Composite endpoint(kidney composite): HR = 0.65(95.0% CI, 0.53 - 0.79)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Canagliflozin Hemihydrate addresses Type 2 diabetes mellitus with established diabetic nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-03-04 | Mitsubishi Tanabe Pharma and Daiichi Sankyo will expire the marketing alliance agreement for the selective DPP-4 inhibitor，“TENELIA® Tablets” and “TENELIA® OD Tablets” and the SGLT2 inhibitor,“CANAGLU® Tablets” | NDA/BLA | Financial terms not disclosed |
| 2020-05-29 | CHMP Issues Positive Opinion to Extend Invokana® (Canagliflozin) Indication to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes | Approved | Financial terms not disclosed |
| 2019-11-04 | Vifor and Janssen collaborate to market Invokana in the US for the treatment of diabetic kidney disease. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Method for continuously producing canagliflozin by using microchannel reactor”. The milestone feed surfaced a patent-application signal described as “Medical use of combination of endothelin a (ETA) receptor antagonist and SGLT-2 inhibitor”. The milestone feed surfaced a patent-application signal described as “A pharmaceutical formulation comprising linagliptin, metformin and a SGLT-2 inhibitor”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
